Published in PLoS One on May 24, 2010
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet (2012) 7.00
Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell (2012) 4.04
P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. Nat Commun (2011) 2.18
Proinvasion metastasis drivers in early-stage melanoma are oncogenes. Cancer Cell (2011) 1.99
Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin Cancer Res (2014) 1.70
IMP-3 promotes migration and invasion of melanoma cells by modulating the expression of HMGA2 and predicts poor prognosis in melanoma. J Invest Dermatol (2014) 1.51
A Systems Biology Approach Identifies FUT8 as a Driver of Melanoma Metastasis. Cancer Cell (2017) 1.39
Genome-wide analysis of the oxyntic proliferative isthmus zone reveals ASPM as a possible gastric stem/progenitor cell marker over-expressed in cancer. J Pathol (2015) 1.38
MALAT1 promotes colorectal cancer cell proliferation/migration/invasion via PRKA kinase anchor protein 9. Biochim Biophys Acta (2014) 1.30
Human melanoma metastasis in NSG mice correlates with clinical outcome in patients. Sci Transl Med (2012) 1.18
Thyroid Growth and Cancer. Eur Thyroid J (2015) 1.11
Protein kinase A activity and anchoring are required for ovarian cancer cell migration and invasion. PLoS One (2011) 1.08
Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. Eur J Cancer (2012) 1.07
Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis. Nature (2015) 1.03
Decoding melanoma metastasis. Cancers (Basel) (2010) 1.02
A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification. Oncotarget (2015) 1.00
Integrative genomics identifies gene signature associated with melanoma ulceration. PLoS One (2013) 0.95
Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proc Natl Acad Sci U S A (2015) 0.93
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest (2016) 0.93
ASPM and microcephalin expression in epithelial ovarian cancer correlates with tumour grade and survival. Br J Cancer (2011) 0.92
Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model. Melanoma Res (2012) 0.91
Analysis of molecular intra-patient variation and delineation of a prognostic 12-gene signature in non-muscle invasive bladder cancer; technology transfer from microarrays to PCR. Br J Cancer (2012) 0.91
SIRT1 promotes proliferation and inhibits the senescence-like phenotype in human melanoma cells. Oncotarget (2014) 0.90
The metastasis suppressor NME1 regulates expression of genes linked to metastasis and patient outcome in melanoma and breast carcinoma. Cancer Genomics Proteomics (2014) 0.86
Sds22/PP1 links epithelial integrity and tumor suppression via regulation of myosin II and JNK signaling. Oncogene (2011) 0.83
Clear cell carcinomas of the ovary: a mono-institutional study of 73 cases in China with an analysis of the prognostic significance of clinicopathological parameters and IMP3 expression. Diagn Pathol (2016) 0.82
A genomic approach to study down syndrome and cancer inverse comorbidity: untangling the chromosome 21. Front Physiol (2015) 0.82
microRNA-7-5p inhibits melanoma cell proliferation and metastasis by suppressing RelA/NF-κB. Oncotarget (2016) 0.82
ZBTB7A Suppresses Melanoma Metastasis by Transcriptionally Repressing MCAM. Mol Cancer Res (2015) 0.81
HEDGEHOG/GLI-E2F1 axis modulates iASPP expression and function and regulates melanoma cell growth. Cell Death Differ (2015) 0.81
FBXW7 modulates cellular stress response and metastatic potential through HSF1 post-translational modification. Nat Cell Biol (2015) 0.81
Expression of the oncofetal protein IGF2BP3 in endometrial clear cell carcinoma: assessment of frequency and significance. Hum Pathol (2013) 0.81
Identification of candidate driver genes in common focal chromosomal aberrations of microsatellite stable colorectal cancer. PLoS One (2013) 0.80
Chromosome 10, frequently lost in human melanoma, encodes multiple tumor-suppressive functions. Cancer Res (2014) 0.80
An attempt at a molecular prediction of metastasis in patients with primary cutaneous melanoma. PLoS One (2012) 0.79
BMI1 induces an invasive signature in melanoma that promotes metastasis and chemoresistance. Genes Dev (2015) 0.79
Up-regulation of Imp3 confers in vivo tumorigenicity on murine osteosarcoma cells. PLoS One (2012) 0.78
Centrosomal AKAP350 and CIP4 act in concert to define the polarized localization of the centrosome and Golgi in migratory cells. J Cell Sci (2015) 0.77
Genomics screens for metastasis genes. Cancer Metastasis Rev (2012) 0.77
Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells. Cell Death Dis (2016) 0.77
Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanoma. Nat Commun (2016) 0.77
Loss of tumor suppressors KAI1 and p27 identifies a unique subgroup of primary melanoma patients with poor prognosis. Oncotarget (2015) 0.76
Metastasis suppressor NME1 regulates melanoma cell morphology, self-adhesion and motility via induction of fibronectin expression. Exp Dermatol (2015) 0.76
The best of both worlds - managing the cancer, saving the bone. Nat Rev Endocrinol (2015) 0.75
The epidermal polarity protein Par3 is a non-cell autonomous suppressor of malignant melanoma. J Exp Med (2017) 0.75
IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin. Sci Rep (2016) 0.75
A metabolic link between the urea cycle and cancer cell proliferation. Mol Cell Oncol (2016) 0.75
AKAP-9 promotes colorectal cancer development by regulating Cdc42 interacting protein 4. Biochim Biophys Acta (2016) 0.75
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. Br J Cancer (2017) 0.75
Thin and thick primary cutaneous melanomas reveal distinct patterns of somatic copy number alterations. Oncotarget (2016) 0.75
Microarray Analysis of Differentially-Expressed Genes Encoding CYP450 and Phase II Drug Metabolizing Enzymes in Psoriasis and Melanoma. Pharmaceutics (2016) 0.75
NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma. Oncogene (2017) 0.75
Modeling Genomic Instability and Selection Pressure in a Mouse Model of Melanoma. Cell Rep (2017) 0.75
Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics (2004) 24.18
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature (2000) 15.53
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A (2004) 10.47
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature (2008) 8.42
High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A (2005) 6.52
Genetic determinants of cancer metastasis. Nat Rev Genet (2007) 6.38
Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci U S A (2006) 6.33
Rac activation and inactivation control plasticity of tumor cell movement. Cell (2008) 6.01
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell (2006) 4.68
Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene (2003) 4.52
Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev (2006) 4.24
Copy number variation at 1q21.1 associated with neuroblastoma. Nature (2009) 4.10
Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res (2004) 3.83
Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res (2009) 3.72
Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst (2006) 3.17
The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A (2005) 3.05
GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature (2009) 2.77
Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res (2007) 2.51
High-resolution global profiling of genomic alterations with long oligonucleotide microarray. Cancer Res (2004) 2.45
The LAR transmembrane protein tyrosine phosphatase and a coiled-coil LAR-interacting protein co-localize at focal adhesions. EMBO J (1995) 2.22
Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. J Clin Oncol (2003) 2.18
Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res (2003) 2.18
Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays. Oncogene (2007) 2.14
IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Hum Pathol (2009) 1.80
Genomic profiling of malignant melanoma using tiling-resolution arrayCGH. Oncogene (2007) 1.72
Chromosomal alterations in the clonal evolution to the metastatic stage of squamous cell carcinomas of the lung. Br J Cancer (2000) 1.65
NEDD9 promotes oncogenic signaling in mammary tumor development. Cancer Res (2009) 1.53
CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. Cancer Res (2006) 1.49
Genomic alterations in primary gastric adenocarcinomas correlate with clinicopathological characteristics and survival. Cell Oncol (2004) 1.46
Hypermethylation and expression regulation of secreted frizzled-related protein genes in colorectal tumor. World J Gastroenterol (2006) 1.45
Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis. J Natl Cancer Inst (2008) 1.36
p38 mitogen-activated protein kinase pathway is involved in protein kinase Calpha-regulated invasion in human hepatocellular carcinoma cells. Cancer Res (2007) 1.34
KiSS1 suppresses metastasis in human ovarian cancer via inhibition of protein kinase C alpha. Clin Exp Metastasis (2005) 1.33
Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther (2006) 1.32
Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas. Clin Cancer Res (2008) 1.31
Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance. Cancer Res (2006) 1.29
Polymorphism discovery in 62 DNA repair genes and haplotype associations with risks for lung and head and neck cancers. Carcinogenesis (2007) 1.27
The association of chromosome 8p deletion and tumor metastasis in human hepatocellular carcinoma. Cancer Res (1999) 1.25
Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. Int J Cancer (2007) 1.21
Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer. BMC Cancer (2006) 1.20
Comparison of DNA gains and losses in primary renal clear cell carcinomas and metastatic sites: importance of 1q and 3p copy number changes in metastatic events. Cancer Res (1997) 1.18
A gene expression signature associated with survival in metastatic melanoma. J Transl Med (2006) 1.13
Melanocyte expression of survivin promotes development and metastasis of UV-induced melanoma in HGF-transgenic mice. Cancer Res (2007) 1.10
Genomic imbalances of 7p and 17q in malignant peripheral nerve sheath tumors are clinically relevant. Genes Chromosomes Cancer (1999) 1.09
Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer. Oncogene (2003) 1.05
Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma. Ann Surg Oncol (2009) 1.03
IL-1 beta induces urokinase-plasminogen activator expression and cell migration through PKC alpha, JNK1/2, and NF-kappaB in A549 cells. J Cell Physiol (2009) 1.02
Gain of 1q and loss of 9q21.3-q32 are associated with a less favorable prognosis in papillary thyroid carcinoma. Genes Chromosomes Cancer (2001) 0.94
A translocation breakpoint disrupts the ASPM gene in a patient with primary microcephaly. Eur J Hum Genet (2004) 0.91
Comparative genomic hybridization analysis suggests a gain of chromosome 7p associated with lymph node metastasis in non-small cell lung cancer. Oncol Rep (2001) 0.91
Effects of fibulin-5 on attachment, adhesion, and proliferation of primary human endothelial cells. Biochem Biophys Res Commun (2006) 0.88
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell (2004) 31.38
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
International network of cancer genome projects. Nature (2010) 20.35
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. EMBO J (2008) 12.89
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
A landscape of driver mutations in melanoma. Cell (2012) 12.61
WHO-EORTC classification for cutaneous lymphomas. Blood (2005) 12.14
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell (2010) 11.20
Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science (2013) 10.87
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science (2007) 10.60
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell (2003) 9.81
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell (2007) 8.94
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature (2004) 8.76
Highly recurrent TERT promoter mutations in human melanoma. Science (2013) 8.40
Identification of cells initiating human melanomas. Nature (2008) 8.28
Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A (2004) 7.96
Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science (2003) 7.86
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Pten dose dictates cancer progression in the prostate. PLoS Biol (2003) 7.62
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 7.36
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet (2009) 7.26
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet (2012) 7.00
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med (2007) 6.55
High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A (2005) 6.52
Telomere dysfunction induces metabolic and mitochondrial compromise. Nature (2011) 6.36
Glioblastoma stem-like cells give rise to tumour endothelium. Nature (2010) 6.18
Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A (2006) 5.90
An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet (2003) 5.82
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature (2007) 5.65
Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell (2007) 5.62
A genetic screen for candidate tumor suppressors identifies REST. Cell (2005) 5.61
NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell (2007) 5.20
Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol (2006) 5.10
The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med (2004) 5.01
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature (2008) 5.00
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature (2005) 4.97
miR-19 is a key oncogenic component of mir-17-92. Genes Dev (2009) 4.95
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell (2011) 4.90
Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res (2006) 4.80
Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell (2007) 4.75
Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell (2008) 4.71
The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet (2005) 4.70
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell (2006) 4.68
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature (2011) 4.57